Clinical Trials Browser

Breast Cancer Metastatic

NCT04113863 2025-12-18

ATRA

Phase 2 Terminated

76 enrolled

Breast

Breast Neoplasm Female

NCT04256941 2024-12-27

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

Phase 2 Terminated

4 enrolled 7 charts

Breast

Breast Neoplasms

NCT04714619 2023-12-19

CAILA

Phase 2 Terminated

2 enrolled

Breast

Advanced Breast Cancer

NCT02585388 2023-09-06

CHEOPS

Phase 2 Terminated

120 enrolled

Breast

Breast Neoplasms

NCT03874325 2022-05-31

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

Phase 2 Terminated

17 enrolled 10 charts

Breast

Breast Neoplasms

NCT02000596 2022-05-27

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

Phase 2 Terminated

2 enrolled 7 charts

Breast

Breast Neoplasms

NCT01234532 2022-05-03

0927GCC

Phase 2 Terminated

5 enrolled 7 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02269670 2022-04-05

Phase II Study of Everolimus Beyond Progression

Phase 2 Terminated

3 enrolled 4 charts

Breast

Breast Neoplasms

NCT03220178 2022-01-06

PRECYCLE

Phase 4 Terminated

532 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT02730091 2021-02-01

VICTORIANE

Phase 3 Terminated

98 enrolled

Breast

Breast Neoplasms

NCT01394211 2018-07-26

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Phase 2 Terminated

2 enrolled 3 charts

Breast

Breast Neoplasms, Breast Neoplasms, Male

NCT01776008 2018-05-08

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

Phase 2 Terminated

16 enrolled 5 charts

Breast

Breast Neoplasms

NCT01484041 2018-02-09

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Phase 1/2 Terminated

12 enrolled 7 charts

Breast

Breast Neoplasms

NCT00684216 2017-09-14

Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer

Phase 2/3 Terminated

10 enrolled

Breast

Breast Neoplasms, Neoplasm Metastasis

NCT00661531 2017-04-12

Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy

Phase 2 Terminated

11 enrolled 8 charts

Breast

Breast Neoplasms

NCT01262274 2015-05-21

Neo-ACET BC

Phase 2 Terminated

57 enrolled

Breast

Breast Neoplasms

NCT01368263 2015-04-03

Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer

Phase 2 Terminated

8 enrolled 5 charts

Breast

Breast Neoplasms

NCT00053911 2014-12-16

Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer

Phase 3 Terminated

Breast

Breast Neoplasms

NCT01151215 2014-07-25

MINT

Phase 2 Terminated

482 enrolled 10 charts

Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00555477 2014-06-19

Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure

Phase 2 Terminated

69 enrolled 6 charts

Breast

Breast Neoplasms

NCT00206414 2013-02-05

Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer

Phase 2 Terminated

15 enrolled

Breast

Breast Neoplasms

NCT00437359 2012-03-30

Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer

Phase 2 Terminated

240 enrolled

Breast

Breast Neoplasms

NCT00555867 2011-12-23

PACT

Terminated

4,923 enrolled

Breast

Breast Neoplasms, Patient Compliance

Clinical Trials

AMEERA-3

ATRA

Aromatase Inhibitor Therapy With or Without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer With an ERS1 Activating Mutation, the INTERACT Study

CAILA

CHEOPS

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

1303GCC: Trastuzmab & Pertuzumab With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over.

0927GCC

Phase II Study of Everolimus Beyond Progression

PRECYCLE

VICTORIANE

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer

Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer

Second-line Endocrine Treatment Followed by Capecitabine Versus Capecitabine Followed by Endocrine Treatment in Patients With Metastatic ER Positive Breast Cancer

Estrogen in Postmenopausal Women With ER Positive Metastatic Breast Cancer After Failure of Sequential Endocrine Therapy

Neo-ACET BC

Goserelin and Letrozole or Anastrozole in Premenopausal Patients With Stage II-III Estrogen Receptor-Positive Breast Cancer

Combination Chemotherapy Compared With Observation After Surgery in Treating Women With Relapsed Nonmetastatic Breast Cancer

MINT

Aromatase Inhibitors in Premenopausal Breast Cancer Patients With Chemotherapy-Induced Ovarian Failure

Arimidex/Faslodex/Iressa Study: A Trial Using Arimidex, Faslodex and Iressa in Women With Breast Cancer

Antiestrogen vs Aromatase Inhibitor After Adjuvant Chemotherapy for Breast Cancer

PACT